Connect with us


Eli Lilly executive anticipates release of obesity pill trial results in April 2025, reports Health News on ET HealthWorld



Eli Lilly exec expects obesity pill data in April 2025, Health News, ET HealthWorld

Eli Lilly, a pharmaceutical company, is set to unveil data from its late-stage trial on an experimental obesity pill called orforglipron in April 2025. The pill belongs to a class of drugs known as incretins, designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow down the rate at which the stomach empties, and decrease appetite.

The President of Lilly Diabetes and Obesity, Patrik Jonsson, mentioned at a Goldman Sachs healthcare conference that while the drug may not directly treat diseases like Alzheimer’s, it could potentially help with underlying conditions such as obesity and stroke, which are precursors to cognitive decline.

The trial results are highly anticipated as they could provide valuable insights into the efficacy and safety of orforglipron in treating obesity. The pharmaceutical industry is closely monitoring the developments in this area, as the global obesity epidemic continues to be a major health concern.

The data from this late-stage trial could potentially pave the way for the approval and commercialization of orforglipron as a new treatment option for obesity. Keep an eye out for further updates on this groundbreaking research in the coming months.

Click to comment

You must be logged in to post a comment Login

Leave a Reply